Tango Therapeutics Inc research snapshot
TNGX AI stock analysis reads Tango Therapeutics as a clinical-stage precision oncology company developing novel synthetic lethality therapies, with its lead PRMT5 inhibitor program showing encouraging early clinical data. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $31.06, market capitalization was about $5.04 billion, and the stock traded near its 52-week high after an extraordinary rally from a $5.60 low. Tango recently reported a 92% objective response rate for its vopimetostat and daraxonrasib combination in pancreatic cancer and completed a $600 million public offering in June 2026. The core question is whether pipeline catalysts can deliver commercial value before cash runway becomes a concern. This is informational research and not investment advice.
Current price
$31.06
Market cap
$5.04 billion
AI score
62 / 100
Rating
High-risk clinical-stage biotech with strong pipeline momentum
Trend status
Strong uptrend from 52-week low with recent consolidation near highs
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Tango Therapeutics is a clinical-stage precision oncology company using synthetic lethality to develop targeted cancer therapies, primarily its PRMT5 inhibitor program. It has no approved products or recurring revenue. | Medium |
| Moat | The potential moat comes from proprietary synthetic lethality biology, IP around PRMT5 inhibition in MTAP-deleted tumors, and first-mover advantage in specific biomarker-defined patient populations. This is unproven until regulatory approval. | Low |
| Management | Led by experienced biotech management with scientific founders from leading cancer genetics institutions. Recent addition of Robert Azelby to the board adds commercial-stage biotech expertise. Capital allocation demonstrated by the $600M June 2026 offering. | Medium |
| Financial trend | Pre-revenue biotech with TTM net loss around $107 million through Q1 2026. Revenue of $53.81M in Q3 2025 reflected a collaboration milestone. Cash position significantly strengthened by June 2026 $600M offering, extending runway into late 2028 or beyond. | Medium |
| Valuation | At $31.06 with no approved products, valuation is driven by pipeline probability-adjusted peak sales estimates. Analyst targets range from $24 to $66 with a consensus near $42. The $5B market cap reflects optimism around PRMT5 and the 92% ORR pancreatic cancer data. | Medium |
| Technical trend | TNGX traded above all major moving averages (5, 20, 50, 100, 200-day) with a strong uptrend. 14-day RSI was 58, ADX near 30 confirmed a trending market. Price consolidated near the 52-week high around $34 after the massive rally. | Medium-high |
| Risk level | Key risks are clinical trial failure, regulatory denial, cash burn and dilution, single-pipeline dependency, competitive PRMT5 programs, and binary outcomes typical of clinical-stage biotech investing. | High |
| AI confidence | Medium-high confidence for technical levels, financial runway calculations, and risk identification. Lower confidence for clinical probability of success, regulatory timelines, and peak sales estimates. | Medium data confidence |
| Investment certainty | Low certainty. TNGX has demonstrated strong clinical momentum and analyst support, but clinical-stage biotech outcomes are inherently binary and unpredictable. Position sizing must account for the possibility of total capital loss. | Low |
TNGX AI stock forecast
The TNGX AI stock forecast uses scenario ranges around the $31.06 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires continued positive clinical data, successful regulatory filings, and commercial partnership validation. The base case assumes pipeline progress with periodic financing events. The bearish case assumes clinical setbacks or competitive displacement.
$55 to $75
More likely if vopimetostat (PRMT5 inhibitor) delivers positive registration-enabling data, regulatory pathways are clarified for MTAP-deleted solid tumors, Tango secures a high-value partnership, and the market assigns a premium multiple for the precision oncology platform.
$28 to $42
More likely if pipeline progresses with incremental clinical data readouts, Tango continues periodic capital raises, and the stock trades in line with peer clinical-stage precision oncology companies at similar stages.
$5 to $15
More likely if key clinical trials miss endpoints, FDA places a clinical hold, competitive PRMT5 programs (from Amgen, Mirati, or others) advance faster, or cash runway concerns emerge despite the recent $600M raise.
TNGX AI technical analysis
TNGX AI technical analysis starts from the $31.06 close on July 10, 2026 used for this July 12 static page. Barchart technical data showed the stock above the 5-day ($30.46), 20-day ($30.40), 50-day ($25.85), 100-day ($22.40), and 200-day ($15.96) moving averages, confirming a powerful uptrend. The 14-day RSI was 58.01, ADX was 29.89 indicating a trending market. ATR of $2.13 reflected high daily volatility typical of clinical-stage biotech. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $31.06 | Latest verified close used for this page as of the July 12, 2026 data cutoff, based on Google Finance and Barchart data. |
| Near support | $28.90 to $30.40 | Support zone around the July 10 intraday low ($28.91) and 20-day moving average ($30.40) area reported by Barchart. |
| Secondary support | $25.00 to $25.85 | The 50-day moving average area around $25.85. A sustained break below this level would weaken the intermediate uptrend. |
| Near resistance | $31.48 to $34.39 | The recent high of $31.48 (July 10 intraday high) and the 52-week high at $34.39. A breakout above $34.39 would set a new all-time high. |
| 50-day moving average | About $25.85 | Barchart showed TNGX approximately 20% above the 50-day MA, confirming the intermediate uptrend. |
| 200-day moving average | About $15.96 | TNGX was approximately 95% above its 200-day MA, reflecting the extraordinary 455% rally from the 52-week low. |
| Momentum | RSI 58.01, ADX 29.89 | RSI was in neutral territory with room to run. ADX above 25 confirmed a trending market. +DI (27.97) above -DI (17.78) supported bullish bias. |
| Volume | 3.37 million shares | July 10 volume was below the 20-day average of 5.45M. Volume confirmation is needed for any breakout attempt above $34. |
| Volatility | 14-day ATR near $2.13 | ATR of about 6.8% of share price, reflecting the high volatility typical of clinical-stage biotech. Position sizing must account for potential daily swings of $2 or more. |
| Invalidation | Close below $28.90, then $25.85 | A close below $28.90 would suggest loss of near-term support momentum. A break below the 50-day area around $25.85 would weaken the intermediate trend. |
TNGX AI trading strategy
The TNGX AI trading strategy is a rules-based framework, not personalized advice. It combines clinical-stage biotech catalysts, technical confirmation, position sizing, and clear invalidation levels.
Monitor clinical trial data readout dates, regulatory submission milestones, and partnership announcements. A positive data release with above-average volume breakout above $34.39 would signal continued momentum.
Clinical-stage biotech moves sharply on binary events. Position size should be small relative to portfolio. Define maximum loss before each catalyst event.
Look for TNGX to hold above the 20-day moving average near $30.40 with constructive volume. A clean breakout above $34.39 with volume above the 5M average would confirm trend continuation after consolidation.
A daily close below the 50-day MA near $25.85 or a reversal from the 52-week high zone should reduce confidence in the uptrend.
Track cash runway from quarterly filings, clinical trial enrollment and data timelines, competitive PRMT5 landscape, insider buying or selling, and analyst rating changes.
Lower the rating if a key clinical trial misses its primary endpoint, FDA places a clinical hold, or Tango needs to raise capital at distressed levels. The stock can gap down 30-50% on negative binary events.
Investment research summary
Tango Therapeutics discovers and develops precision oncology treatments targeting genetic vulnerabilities in cancer cells through synthetic lethality. Its lead program targets PRMT5 in MTAP-deleted tumors, a genetically defined patient population with high unmet need across multiple cancer types.
The potential moat depends on proprietary synthetic lethality biology, composition-of-matter patents, clinical data exclusivity, and first-mover advantage in MTAP-deleted solid tumors. The moat is unproven until regulatory approval and will face competition from Amgen, Mirati, and other companies developing PRMT5 inhibitors.
The thesis fails if the PRMT5 program shows insufficient differentiation versus competitors, registration trials miss endpoints, the 92% ORR pancreatic cancer data does not replicate in larger studies, FDA requires additional trials, or Tango burns through its $600M raise without achieving value-inflection milestones.
Led by experienced biotech executives with strong scientific founders. Appointment of Robert Azelby to the board adds commercial-stage oncology expertise. The team successfully raised $600M in June 2026, demonstrating capital markets credibility.
Precision oncology and biomarker-driven therapies represent a long-term secular trend in cancer treatment. The synthetic lethality approach is gaining traction as the industry moves beyond traditional cytotoxic chemotherapy toward genetically targeted therapies.
At roughly $5 billion market cap with no approved products, TNGX trades at a premium to many clinical-stage biotechs, reflecting enthusiasm around the 92% ORR pancreatic cancer data and the PRMT5 program. Analyst targets ($24-$66, consensus $42) imply a wide range of outcomes consistent with binary biotech risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TNGX price | $31.06 close on July 10, 2026 | Google Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.04 billion, verified as $31.06 x 162.82M shares (0.34% deviation) | financial_rigor.py market cap verification and Google Finance | July 12, 2026 |
| Shares outstanding | 162.82 million (post-June 2026 offering) | Google Finance and financial_rigor.py cross-validation | July 12, 2026 |
| Q1 2026 net loss | -$45.51 million | Google Finance income statement data | July 12, 2026 |
| TTM net loss | Approximately -$107 million (Q2 2025 through Q1 2026) | Summed from Google Finance quarterly data | July 12, 2026 |
| Cash and securities | Estimated $800M+ post-June 2026 $600M offering (prior $300M+ cash) | SEC filings and company press releases | July 12, 2026 |
| EPS (TTM) | -$0.83 | Google Finance summary data | July 12, 2026 |
| Cash runway estimate | Extended into late 2028 or beyond with $600M June 2026 raise | Calculated from cash balance and quarterly burn rate | July 12, 2026 |
| Analyst consensus | 11 analysts: 10 Buy, 1 Hold. Average target $42.00 (range $24-$66) | Google Finance analyst ratings | July 12, 2026 |
| Moving averages and momentum | 50-day MA about $25.85, 200-day MA about $15.96, RSI 58.01, ADX 29.89 | Barchart technical analysis data | July 12, 2026 |
This TNGX AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Clinical-stage biotechnology investments carry risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
